Matthew J Ellis

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. pmc First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
    Z W Wong
    National Cancer Centre, Singapore
    Br J Cancer 90:20-5. 2004
  2. pmc Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
    Lyndsay N Harris
    Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Breast Cancer Res 8:R66. 2006
  3. pmc The molecular portraits of breast tumors are conserved across microarray platforms
    Zhiyuan Hu
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    BMC Genomics 7:96. 2006
  4. pmc "I'm pregnant and I have breast cancer"
    Michael J Naughton
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    BMC Cancer 7:93. 2007
  5. ncbi request reprint Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy
    Matthew J Ellis
    Washington University School of Medicine, Section of Medical Oncology and Breast Cancer Program, St Louis, Missouri, USA
    Ann Surg Oncol 11:9S-17S. 2004
  6. ncbi request reprint Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data
    Matthew J Ellis
    Siteman Comprehensive Cancer Center and Washington University School of Medicine, St Louis, MO 63110, USA
    Curr Med Res Opin 22:2479-87. 2006
  7. ncbi request reprint Neoadjuvant endocrine therapy as a drug development strategy
    Matthew J Ellis
    Washington University School of Medicine, St Louis, Missouri, USA
    Clin Cancer Res 10:391S-5S. 2004
  8. pmc Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
    Matthew J Ellis
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63119, USA
    Breast Cancer Res Treat 119:379-90. 2010
  9. pmc Whole-genome analysis informs breast cancer response to aromatase inhibition
    Matthew J Ellis
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri 63110, USA
    Nature 486:353-60. 2012
  10. pmc Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
    Matthew J Ellis
    Siteman Cancer Center, Washington University in St Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Clin Oncol 29:2342-9. 2011

Detail Information

Publications75

  1. pmc First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?
    Z W Wong
    National Cancer Centre, Singapore
    Br J Cancer 90:20-5. 2004
    ....
  2. pmc Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342
    Lyndsay N Harris
    Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
    Breast Cancer Res 8:R66. 2006
    ..We analyzed data from CALGB 9342, which tested three doses of paclitaxel in women with advanced disease, to determine whether response and outcomes differed according to HER2, hormone receptor, and p53 status...
  3. pmc The molecular portraits of breast tumors are conserved across microarray platforms
    Zhiyuan Hu
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    BMC Genomics 7:96. 2006
    ..To overcome this problem we used publicly available breast cancer gene expression data sets and a novel approach to data fusion, in order to validate a new breast tumor intrinsic list...
  4. pmc "I'm pregnant and I have breast cancer"
    Michael J Naughton
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    BMC Cancer 7:93. 2007
    ..There is general consensus that both surgery and chemotherapy are relatively safe after the first trimester of pregnancy. It is generally agreed that therapeutic radiation, if necessary, should be delayed until completion of pregnancy...
  5. ncbi request reprint Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy
    Matthew J Ellis
    Washington University School of Medicine, Section of Medical Oncology and Breast Cancer Program, St Louis, Missouri, USA
    Ann Surg Oncol 11:9S-17S. 2004
    ..Ongoing investigations are examining gene expression profile changes associated with neoadjuvant endocrine therapy, as well as inhibitors of growth factor signaling that may modulate tamoxifen resistance...
  6. ncbi request reprint Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data
    Matthew J Ellis
    Siteman Comprehensive Cancer Center and Washington University School of Medicine, St Louis, MO 63110, USA
    Curr Med Res Opin 22:2479-87. 2006
    ..This review will compare the current available efficacy, safety, and cost-effectiveness data for AIs in the initial adjuvant and switch adjuvant settings...
  7. ncbi request reprint Neoadjuvant endocrine therapy as a drug development strategy
    Matthew J Ellis
    Washington University School of Medicine, St Louis, Missouri, USA
    Clin Cancer Res 10:391S-5S. 2004
    ..However, the optimal clinical investigative approaches, analytical techniques, and appropriate surrogate end points have yet to be identified and are the subject of several ongoing or planned clinical studies...
  8. pmc Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer
    Matthew J Ellis
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63119, USA
    Breast Cancer Res Treat 119:379-90. 2010
    ..Nonetheless, as with other recent studies, a favorable interaction between PIK3CA KD mutation and prognosis was detected. The mechanism for the favorable prognostic impact of PIK3CA mutation status therefore remains unexplained...
  9. pmc Whole-genome analysis informs breast cancer response to aromatase inhibition
    Matthew J Ellis
    Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri 63110, USA
    Nature 486:353-60. 2012
    ..Prospective clinical trials based on these findings will require comprehensive genome sequencing...
  10. pmc Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
    Matthew J Ellis
    Siteman Cancer Center, Washington University in St Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Clin Oncol 29:2342-9. 2011
    ..To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations...
  11. pmc Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
    Matthew J Ellis
    Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63119, USA
    Breast Cancer Res Treat 116:371-8. 2009
    ..Expression of aromatase by malignant breast epithelial cells and/or the surrounding stroma implies local estrogen production that could influence the outcome of endocrine therapy for breast cancer...
  12. pmc Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
    Matthew J Ellis
    Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, St Louis, MO 63119, USA
    J Natl Cancer Inst 100:1380-8. 2008
    ....
  13. ncbi request reprint Predicting endocrine therapy responsiveness in breast cancer
    Cynthia X Ma
    Section of Medical Oncology, Division of Oncology, Department of Internal Medicine, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Oncology (Williston Park) 23:133-42. 2009
    ..This article reviews ongoing progress in the effort to identify predictors of endocrine therapy responsiveness for breast cancer and discusses the value of "pre-treatment" vs "on-treatment" tumor profiling for predicting outcomes...
  14. pmc Letrozole in the neoadjuvant setting: the P024 trial
    Matthew J Ellis
    Medical Oncology, Washington University, Campus Box 8056, 660 Euclid Ave, St Louis, MO 63110, USA
    Breast Cancer Res Treat 105:33-43. 2007
    ..0009). Thus, neoadjuvant letrozole is safe and superior to tamoxifen in the treatment of postmenopausal women with HR+ locally advanced breast cancer...
  15. pmc Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
    Cesar G Sanchez
    Department of Hematology Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Lira 85, 4th Floor, Santiago 8330023, Chile
    Breast Cancer Res 13:R21. 2011
    ....
  16. pmc Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models
    Siguang Xu
    Section of Breast Oncology, Division of Oncology, Department of Internal Medicine, Washington University in St Louis, School of Medicine, St Louis, MO, USA
    Mol Cancer Ther 12:1665-75. 2013
    ..Our results provide a preclinical rationale for future clinical investigation of this combination in basal-like breast cancer with loss of PTEN...
  17. pmc Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
    Shunqiang Li
    Section of Breast Oncology, Division of Oncology, Department of Internal Medicine, Washington University in St Louis, St Louis, MO 63110, USA Siteman Cancer Center Breast Cancer Program, Washington University in St Louis, St Louis, MO 63110, USA
    Cell Rep 4:1116-30. 2013
    ..The originating tumor genome provides a benchmark for assessing genetic drift and clonal representation after transplantation. ..
  18. pmc Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
    Cynthia X Ma
    Section of Breast Oncology, Division of Oncology, Washington University School of Medicine, St Louis, Missouri 63110 1093, USA
    J Clin Invest 122:1541-52. 2012
    ..In addition, knockdown of p53 sensitized WU-BC3 tumors to the combination therapy. These results demonstrate that p53 is a major determinant of how TNBCs respond to therapies that combine DNA damage with Chk1 inhibition...
  19. pmc Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study
    Matthew J Ellis
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    JAMA 302:774-80. 2009
    ..Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy...
  20. pmc PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer
    Robert J Crowder
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Cancer Res 69:3955-62. 2009
    ..Our results suggest that PI3K inhibitors should target both p110alpha and p110beta catalytic subunits, whether wild-type or mutant, and be combined with endocrine therapy for maximal efficacy when treating ER(+) breast cancer...
  21. ncbi request reprint Neoadjuvant endocrine therapy for locally advanced breast cancer
    Cynthia X Ma
    Department of Oncology, Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Semin Oncol 33:650-6. 2006
    ..In this review, we outline the rationale for preoperative endocrine therapy, and consider predictive models for endocrine therapy responsiveness in this setting...
  22. ncbi request reprint The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers
    P Kelly Marcom
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8056, St Louis, MO, USA
    Breast Cancer Res Treat 102:43-9. 2007
    ..The efficacy of the aromatase inhibitor letrozole in combination with trastuzumab was therefore tested in a Phase 2 study...
  23. ncbi request reprint Neoadjuvant endocrine therapy for breast cancer: an overlooked option?
    Zee Wan Wong
    National Cancer Centre, Singapore
    Oncology (Williston Park) 18:411-20; discussion 421, 424, 429 passim. 2004
    ....
  24. pmc Mutational analysis of breast cancer: guiding personalized treatments
    Matthew J Ellis
    Division of Medical Oncology, Section of Breast Oncology, Washington University School of Medicine, Siteman Cancer Center, 660 South Euclid Ave, CB 8069, St Louis, MO 63110, USA Electronic address
    Breast 22:S19-21. 2013
    ..This article reviews conclusions from recent breast cancer 'omics profiling' papers and considers pathways forward for extracting medically valuable information from large dimension data sets...
  25. ncbi request reprint Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
    Matthew J Ellis
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, Campus Box 8056, 660 S Euclid Ave, St Louis, MO 63110, USA
    J Clin Oncol 24:3019-25. 2006
    ....
  26. pmc A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
    Paula M Fracasso
    Department of Internal Medicine, Alvin J Siteman Cancer Center and Washington University School of Medicine, St Louis, MO, USA
    Cancer Chemother Pharmacol 67:1225-37. 2011
    ..We conducted a Phase I study to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic, and pharmacodynamic effects of UCN-01 and irinotecan in patients with resistant solid tumors...
  27. pmc Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
    Christopher A Miller
    McDonnell Genome Institute, Washington University School of Medicine, St Louis, Missouri 63108, USA
    Nat Commun 7:12498. 2016
    ..The observed clonal complexity of the ER+ breast cancer genome suggests that precision medicine approaches based on genomic analysis of a single specimen are likely insufficient to capture all clinically significant information. ..
  28. doi request reprint A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
    Cynthia X Ma
    Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri
    Clin Cancer Res 22:2650-8. 2016
    ....
  29. pmc A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
    Cynthia X Ma
    Section of Breast Oncology, Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid Avenue, P O Box 8056, St Louis, MO 63110, USA
    Breast Cancer Res Treat 139:145-53. 2013
    ..019) on day 2. Compared with day 2, there were significant increases in the serum levels of IGF-1 (p < 0.001), IGF-2 (p = 0.001), and IGFBP-3 (p = 0.019) on day 8. A phase II study in women with metastatic breast cancer is ongoing...
  30. pmc Racial differences in outcomes of triple-negative breast cancer
    Jose M Pacheco
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA
    Breast Cancer Res Treat 138:281-9. 2013
    ..We conclude that race did not significantly affect the clinical presentation and outcome of TNBC in this single center study where patients received similar therapy and follow-up...
  31. doi request reprint Neoadjuvant endocrine therapy for breast cancer
    Jane S Chawla
    Division of Oncology, Department of Medicine, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Surg Oncol Clin N Am 19:627-38. 2010
    ....
  32. ncbi request reprint A luminal breast cancer genome atlas: progress and barriers
    Matthew J Ellis
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63119, USA
    J Steroid Biochem Mol Biol 106:125-9. 2007
    ....
  33. doi request reprint Incorporating genomics into breast cancer clinical trials and care
    Adel Tabchy
    Authors Affiliation Section of Breast Oncology, Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri
    Clin Cancer Res 19:6371-9. 2013
    ....
  34. pmc Activating HER2 mutations in HER2 gene amplification negative breast cancer
    Ron Bose
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Cancer Discov 3:224-37. 2013
    ..These findings show that HER2 somatic mutation is an alternative mechanism to activate HER2 in breast cancer and they validate HER2 somatic mutations as drug targets for breast cancer treatment...
  35. doi request reprint Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial
    Antonella L Rastelli
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Breast Cancer Res Treat 129:107-16. 2011
    ..06). Weekly HDD improves AIMSS and may have a positive effect on bone health. Vitamin D supplementation strategies for breast cancer patients on AI should be further investigated...
  36. doi request reprint Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors
    Cynthia X Ma
    Siteman Comprehensive Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Steroids 76:750-2. 2011
    ....
  37. pmc Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium
    Matthew J Ellis
    1Division of Oncology and 2Division of Endocrinology and Metabolism, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 3The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 4Fred Hutchinson Cancer Research Center, Seattle 5Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 6Office of Cancer Clinical Proteomics Research, National Cancer Institute, NIH, Bethesda, Maryland and 7The Jim Ayers Institute for Cancer Detection and Diagnosis, Vanderbilt Ingram Cancer Center, Nashville, Tennessee
    Cancer Discov 3:1108-12. 2013
    ....
  38. pmc The genomic landscape of breast cancer as a therapeutic roadmap
    Matthew J Ellis
    Division of Medical Oncology, Section of Breast Oncology, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Cancer Discov 3:27-34. 2013
    ..In this Prospective, we summarize some of the headline conclusions from 6 recent breast cancer "omics profiling" articles in Nature, with an emphasis on the implications for systemic therapy...
  39. pmc ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer
    Brian A Van Tine
    Division of Oncology, Department of Medicine, Washington University in Saint Louis, St Louis, Missouri 63110, USA
    Cancer Discov 1:287-8. 2011
    ..Promising preclinical evidence by several groups for the combination of an inhibitor of ligand-independent ER, fulvestrant, with PI3K inhibition, has led to the activation of trials evaluating this concept...
  40. doi request reprint Molecular profiling of triple negative breast cancer
    Cynthia X Ma
    Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Breast Dis 32:73-84. 2010
    ..With the advent of whole genome sequencing, we envision further classification of TNBC that is based on genetic abnormalities linked to targeted therapeutics...
  41. pmc Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study
    Mike G Martin
    Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8007, Saint Louis, MO 63110, USA
    Breast Cancer Res Treat 118:593-8. 2009
    ..This association maybe explained by either greater chemotherapy exposure or an interaction between therapy and genetic predisposition...
  42. pmc A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer
    Ying Liu
    Division of Health Behavior Research, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63108, USA
    Breast Cancer Res Treat 124:835-44. 2010
    ..Educating early-stage breast cancer patients about their actual risk could result in more realistic recurrence-risk perceptions, and increasing social support could help alleviate anxiety associated with exaggerated risk perceptions...
  43. ncbi request reprint Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status
    Matthew J Ellis
    Duke University Comprehensive Cancer Center, Campus Box 8056, 660 South Euclid, Durham, NC 27710, USA
    Cancer Res 63:6523-31. 2003
    ....
  44. pmc Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway
    Robert J Crowder
    Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, St Louis, Missouri, USA
    Breast Cancer Res 7:212-4. 2005
    ....
  45. pmc An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors
    Jingqin Luo
    Division of Public Health Sciences, Washington University School of Medicine, St Louis, Missouri Department of Surgery, the Siteman Cancer Center Biostatistics Shared Resource, Washington University School of Medicine, St Louis, Missouri
    J Mol Diagn 19:147-161. 2017
    ..Our study demonstrates an efficient approach to diagnosing rare amplified therapeutic targets with FISH as a confirmatory assay...
  46. pmc A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
    Cynthia X Ma
    Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri
    Clin Cancer Res 22:1583-91. 2016
    ....
  47. pmc US breast cancer mortality trends in young women according to race
    Foluso O Ademuyiwa
    Division of Oncology, Department of Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri
    Cancer 121:1469-76. 2015
    ..In the current study, the authors sought to determine whether there is a differential effect of race and examined mortality trends according to race and age...
  48. pmc Genome remodelling in a basal-like breast cancer metastasis and xenograft
    Li Ding
    The Genome Center at Washington University, St Louis, Missouri 63108, USA
    Nature 464:999-1005. 2010
    ..The differential mutation frequencies and structural variation patterns in metastasis and xenograft compared with the primary tumour indicate that secondary tumours may arise from a minority of cells within the primary tumour...
  49. doi request reprint Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies
    Paula M Fracasso
    Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
    Cancer Chemother Pharmacol 63:451-8. 2009
    ..To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of weekly docosahexaenoic acid-paclitaxel (DHA-paclitaxel), a taxane fatty acid conjugate...
  50. doi request reprint Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer
    Cynthia X Ma
    Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, 63110, St Louis, MO, USA
    Adv Exp Med Biol 882:125-54. 2016
    ..The recognition of somatic mutations and their relationship to endocrine therapy responsiveness opens important opportunities toward this goal. ..
  51. pmc SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution
    Christopher A Miller
    The Genome Institute, Washington University, St Louis, Missouri, United States of America
    PLoS Comput Biol 10:e1003665. 2014
    ..By doing so, we can track tumor evolution and identify the spatial origins of cells resisting therapy. ..
  52. pmc Patterns and functional implications of rare germline variants across 12 cancer types
    Charles Lu
    The McDonnell Genome Institute, Washington University in St Louis, Forest Park Avenue, Campus Box 8501, St Louis, Missouri 63108, USA
    Nat Commun 6:10086. 2015
    ..The scale of this analysis and the somatic-germline integration enable the detection of rare variants that may affect individual susceptibility to tumour development, a critical step toward precision medicine. ..
  53. doi request reprint Mechanisms of aromatase inhibitor resistance
    Cynthia X Ma
    Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, Missouri 63110, USA
    Nat Rev Cancer 15:261-75. 2015
    ....
  54. pmc New concepts in breast cancer genomics and genetics
    Rodrigo Gonçalves
    Breast Cancer Program, Department of Medical Oncology, Washington University School of Medicine, 660 S Euclid Ave, St Louis 63110, MO, USA Siteman Cancer Center, Washington University School of Medicine, 660 S Euclid Ave, St Louis 63110, MO, USA Lester and Sue Smith Breast Center, Baylor College of Medicine, One Baylor Plaza, 320A Cullen MS600, Houston 77030, TX, USA
    Breast Cancer Res 16:460. 2014
    ....
  55. ncbi request reprint Successful targeting of ErbB2 receptors-is PTEN the key?
    Robert J Crowder
    Department of Medicine, Division of Oncology, Washington University School of Medicine and Siteman Cancer Center, Campus Box 8056, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Cancer Cell 6:103-4. 2004
    ..Resistance to trastuzumab occurs when PTEN function is lost, suggesting that PTEN activation is a critical component of the therapeutic effect...
  56. pmc Molecular basis of triple negative breast cancer and implications for therapy
    Parvin F Peddi
    Division of Oncology, Department of Medicine, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Int J Breast Cancer 2012:217185. 2012
    ..These findings have implications for therapeutic target identification and the design of future clinical trials for this aggressive group of breast cancer...
  57. pmc Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness
    Nyam Osor Chimge
    Department of Biochemistry, Institute for Genetic Medicine, USC Epigenome Center, Keck School of Medicine of the University of Southern California, Los Angeles, California 90033, USA
    Clin Cancer Res 18:901-11. 2012
    ..To assess the clinical significance of the interaction between estrogen and Runx2 signaling, previously shown in vitro...
  58. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
    ..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
  59. ncbi request reprint "PIKing" the winner for phosphatidylinositol 3-kinase inhibitors in ErbB2-positive breast cancer: let's not "PTENed" it's easy!
    Matthew J Ellis
    Clin Cancer Res 13:5661-2. 2007
  60. ncbi request reprint Letrozole in the treatment of breast cancer
    Heather S Shaw
    Multidisciplinary Breast Program, Duke University Medical Center, Box 3381, Durham, NC 27710, USA
    Expert Opin Pharmacother 3:607-17. 2002
    ..The object of this review is to provide a reference source on the biochemical, pharmacological and clinical properties of letrozole for clinicians to consider both established and future indications...
  61. ncbi request reprint Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect
    Matthew J Ellis
    Breast Cancer Program, DUMC, Duke University, PO Box 3446, Durham, NC 27710, USA
    J Steroid Biochem Mol Biol 86:301-7. 2003
    ..When enough profiles have been generated it should be possible to detect complex interaction patterns that correctly reclassify ER+ disease into treatment responsive and resistant categories with high probability...
  62. doi request reprint Improving outcomes for patients with hormone receptor-positive breast cancer: back to the drawing board
    Matthew J Ellis
    J Natl Cancer Inst 100:159-61. 2008
  63. ncbi request reprint Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement
    Steven E Come
    Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:327S-330S. 2004
  64. ncbi request reprint Estrogen receptor expression and sensitivity to paclitaxel in breast cancer
    Michele K Dougherty
    Lombardi Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC, USA
    Cancer Biol Ther 3:460-7. 2004
    ..These data suggest that measurements of tumor proliferation may provide more accurate predictive markers for the benefits of adjuvant paclitaxel than ERalpha analysis...
  65. ncbi request reprint Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 351:781-91. 2004
    ..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer...
  66. ncbi request reprint Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
    Daniel F Hayes
    Department of Internal Medicine and the Comprehensive Cancer Center, University of Michigan Health and Hospital System, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 12:4218-24. 2006
    ..In this study, additional follow-up data and CTC levels at subsequent follow-up visits were evaluated...
  67. ncbi request reprint A pilot surrogate end point biomarker trial of perillyl alcohol in breast neoplasia
    Vered Stearns
    Breast Cancer Program, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D C, USA
    Clin Cancer Res 10:7583-91. 2004
    ..We report our experience with the natural compound perillyl alcohol (POH) administered in a short-term surrogate end point biomarker (SEB) protocol, using the "window" between diagnostic and definitive surgery...
  68. ncbi request reprint Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
    Neil L Spector
    Department of Discovery Medicine and Clinical Pharmacology, GlaxoSmithKline, Five Moore Dr, Research Triangle Park, NC 27709 3398, USA
    J Clin Oncol 23:2502-12. 2005
    ..This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies...
  69. ncbi request reprint Role of biologic markers in patient selection and application to disease prevention
    Mitch Dowsett
    Joint Institute of Cancer Research Royal Marsden NHS Trust, Academic Department of Biochemistry, London, United Kingdom
    Am J Clin Oncol 26:S34-9. 2003
    ..Gene expression profiling (microarray analysis), i.e., genomic and proteomic studies, will probably advance the discovery of new biomarkers for breast cancer prevention and treatment...
  70. ncbi request reprint Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Howard A Burris
    The Sarah Cannon Research Institute, 250 25th Avenue N, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 23:5305-13. 2005
    ....
  71. ncbi request reprint Neoadjuvant endocrine therapy for breast cancer: more questions than answers
    Matthew J Ellis
    J Clin Oncol 23:4842-4. 2005
  72. ncbi request reprint Breast cancer gene expression analysis--the case for dynamic profiling
    Matthew J Ellis
    Duke University Breast Cancer Program, Duke University Medical Center, DUMC PO Box 3446, Durham, NC 27710, USA
    Adv Exp Med Biol 532:223-34. 2003
    ..Using breast cancer endocrine therapy as an example our initial approaches to dynamic profiling will be described...
  73. ncbi request reprint Dramatic response of choroidal metastases from breast cancer to a combination of trastuzumab and vinorelbine
    Zee Wan Wong
    National Cancer Center, Singapore
    Breast J 10:54-6. 2004
    ....
  74. ncbi request reprint DASH: a novel analysis method for molecular dynamics simulation data. Analysis of ligands of PPAR-gamma
    David W Salt
    Department of Mathematics, Lion Terrace, Buckingham Building, University of Portsmouth, Portsmouth, PO1 3HE, UK
    J Med Chem 48:3214-20. 2005
    ..DASH was compared with Ward's hierarchical cluster analysis method. The results show that DASH analysis is as good as Ward analysis in some areas (e.g. conformation identification) and is superior in others (e.g. speed and input size)...
  75. ncbi request reprint Functional analysis of the breast cancer genome
    Matthew J Ellis
    J Clin Oncol 24:1649-50. 2006